Author

Tara Peters

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Ana Orive-RamosiD· 1 shared Beau BaarsiD· 1 shared Bijaya GaireiD· 1 shared Dalton DacusiD· 1 shared Evangelia MatenoglouiD· 1 shared Evripidis GavathiotisiD· 1 shared Frank P. McCormickiD· 1 shared Joseph P. Lyssikatos· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ana Orive-RamosORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Binding kinetics enable tumor-selective MAPK and growth suppression by a Type 1 RAF Inhibitor

Mathieu Desaunay, Tara Peters, Evangelia Matenoglou, Beau Baars, Bijaya Gaire, Ana Orive-Ramos, Li Ren, Joseph P. Lyssikatos, Michael Burkard, Dalton Dacus, Matthew J. Sale, Stuart A. Aaronson, Frank P. McCormick, Evripidis Gavathiotis, Stefan David Gross, Poulikos I. Poulikakos

This study identifies ELV-3111, a Type 1 RAF inhibitor that selectively suppresses MAPK and tumor growth by exploiting distinct binding kinetics, showing efficacy in RAS-mutant and BRAF-mutant models.

bioRxiv · Oct 6, 2026 · PreprintCancer Biology